Conferences - Results from #980

Viewing 981-1000 of 11869 articles

ASCO GU 2024: Patient Outcomes After Therapy with 177Lu-PSMA-617 for mCRPC: A Tertiary Center Experience

ASCO GU 2024: Patient-Reported Outcomes in Patients with BRCA1/2-Altered mCRPC Receiving Niraparib with Abiraterone Acetate and Prednisone: Results from MAGNITUDE Study

ASCO GU 2024: Patient-Reported Outcomes with Talazoparib + Enzalutamide vs. Placebo + Enzalutamide in Men with mCRPC: Subgroup Analysis of Patients with Novel Hormonal Therapy Pretreatment in the TALAPRO-2 Study

ASCO GU 2024: Prognostic Value of AI–Driven Tumor Estimation of PSMA PET Total Tumor Burden in Newly Diagnosed High-Volume mHSPC

ASCO GU 2024: Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in mCRPC

ASCO GU 2024: Phase Ib Trial of Erdafitinib Combined with Enfortumab Vedotin Following Platinum and PD-1/L1 Inhibitors for Metastatic Urothelial Carcinoma with FGFR2/3 Genetic Alterations

ASCO GU 2024: OASIS: Survival Outcomes of Apalutamide as a Starting Treatment - Impact in Real-World Patients with mCSPC

ASCO GU 2024: ProstACT GLOBAL: A Phase 3 Study of Best Standard of Care with and without 177Lu-DOTA-rosopatamab (TLX591) for Patients with PSMA Expressing mCRPC Progressing Despite Prior Treatment with a Novel Androgen Axis Drug

ASCO GU 2024: Urinary Minimal Residual Disease Detection Predicts Recurrence in BCG-Unresponsive NIMBC and Quantifies Molecular Response to Nadofaragene Firadenovec

ASCO GU 2024: Real-world Comparison of PSA Response in Patients with mCSPC Treated with Apalutamide or Enzalutamide

ASCO GU 2024: 3TMPO: Prognostic Value of FDG, PSMA, and DOTATATE Uptake on PET Imaging in mCRPC

ASCO GU 2024: ProstAct-SELECT: Safety, Tolerability, and Dosimetry of 177Lu-TLX591 with Best Standard of Care in Patients with PSMA-Expressing mCRPC

ASCO GU 2024: Real-world Treatment Sequences and Time to Discontinuation in the First-line mCRPC Setting

ASCO GU 2024: Population Based Trends in Intravesical Gemcitabine Use Among Patients with High-Risk Non-Muscle Invasive Bladder Cancer

ASCO GU 2024: Reasons for Refusal of or Ineligibility for Radical Cystectomy in Patients with BCG–unresponsive High-Risk NMIBC from the SunRISe-1 Study

ASCO GU 2024: Belzutifan Versus Everolimus in Participants With Previously Treated Advanced Renal Cell Carcinoma: Patient-Reported Outcomes in the Phase 3 LITESPARK-005 Study

ASCO GU 2024: SECuRE: A Dose Escalation/Expansion Study to Assess the Anti-tumor Efficacy of 67Cu-SAR-BisPSMA in Patients With mCRPC

ASCO GU 2024: Insights from CheckMate 67T and Patient-Reported Outcomes in LITESPARK-005 for Advanced RCC

ASCO GU 2024: Neoadjuvant Darolutamide Plus Androgen Deprivation Therapy for High-Risk/Very High-Risk Localized Prostate Cancer: A Multicenter, Open-Labeled, Single-Arm Phase II Trial

ASCO GU 2024: The Role of Radiation in Primary Tumor and Distant Sites in Managing Renal Cell Carcinoma

45
46
47
48
49
50
51
52
53
54